NASDAQ:ANAB

AnaptysBio (ANAB) Stock Forecast, Price & News

$17.96

-0.04 (-0.22%)

(As of 09/29/2023 ET)

Compare

Today's Range: $17.43
▼
$18.09
50-Day Range: $16.74
▼
$20.56
52-Week Range: $16.51
▼
$32.44

Volume: 182,012 shs
Average Volume: 291,710 shs
Market Capitalization: $476.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.75

AnaptysBio MarketRank™ Forecast

Analyst Rating: Hold
2.40 Rating Score
Upside/Downside: 93.5% Upside
$34.75 Price Target
Short Interest: Bearish
20.15% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.80
Based on 2 Articles This Week
Insider Trading: Selling Shares
$116,257 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($6.61) to ($6.99) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Medical Sector

872nd out of 972 stocks

Pharmaceutical Preparations Industry

411th out of 449 stocks

3.2

Analyst's Opinion

Consensus Rating
AnaptysBio has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $34.75, AnaptysBio has a forecasted upside of 93.5% from its current price of $17.96.
Amount of Analyst Coverage
AnaptysBio has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
20.15% of the float of AnaptysBio has been sold short.
Short Interest Ratio / Days to Cover
AnaptysBio has a short interest ratio ("days to cover") of 18, which indicates bearish sentiment.
Change versus previous month
Short interest in AnaptysBio has recently increased by 1.08%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
AnaptysBio does not currently pay a dividend.
Dividend Growth
AnaptysBio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ANAB.

3.2

News and Social Media Coverage

News Sentiment
AnaptysBio has a news sentiment score of 1.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for AnaptysBio this week, compared to 1 article on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $116,257.00 in company stock.
Percentage Held by Insiders
35.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for AnaptysBio are expected to decrease in the coming year, from ($6.61) to ($6.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AnaptysBio is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AnaptysBio is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AnaptysBio has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

ANAB Price History

30 days | 90 days | 365 days | Advanced Chart

ANAB Stock News Headlines

September 25, 2023 | marketbeat.com

Argenx's 28% Surge & Promising Product Propel Investor Confidence (ANAB)

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

September 23, 2023 | americanbankingnews.com

AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Hold" by Brokerages

October 1, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

September 19, 2023 | finance.yahoo.com

Insider Sell: Eric Loumeau Sells 6,000 Shares of AnaptysBio Inc

September 14, 2023 | benzinga.com

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

August 8, 2023 | msn.com

Wedbush Maintains AnaptysBio (ANAB) Neutral Recommendation

August 8, 2023 | benzinga.com

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

July 31, 2023 | marketwatch.com

AnaptysBio Shares Rise 11% After Jemperli Plus Chemotherapy Approved in U.S.

October 1, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

July 7, 2023 | seekingalpha.com

AnaptysBio: Despite Early Successes, Current Situation Does Not Impress

July 6, 2023 | msn.com

AnaptysBio (ANAB) Price Target Increased by 6.91% to 33.15

July 4, 2023 | finance.yahoo.com

Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested five years ago

May 31, 2023 | fool.com

AnaptysBio (NASDAQ: ANAB)

May 30, 2023 | finance.yahoo.com

AnaptysBio Announces Participation in Upcoming Investor Conferences

May 24, 2023 | finance.yahoo.com

Need To Know: The Consensus Just Cut Its AnaptysBio, Inc. (NASDAQ:ANAB) Estimates For 2023

May 22, 2023 | msn.com

JP Morgan Upgrades AnaptysBio (ANAB)

May 20, 2023 | finance.yahoo.com

Wall Street Analysts Predict a 45.12% Upside in AnaptysBio, Inc. (ANAB): Here's What You Should Know

May 18, 2023 | msn.com

AnaptysBio initiated Outperform at TD Cowen on anti-inflammatory agents

May 13, 2023 | msn.com

Guggenheim Maintains AnaptysBio (ANAB) Buy Recommendation

May 13, 2023 | msn.com

Wedbush Reiterates AnaptysBio (ANAB) Neutral Recommendation

May 12, 2023 | finanznachrichten.de

AnaptysBio, Inc.: AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

May 11, 2023 | benzinga.com

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

May 4, 2023 | finance.yahoo.com

Wall Street Analysts Predict a 45.12% Upside in AnaptysBio, Inc. (ANAB): Here's What You Should Know

May 2, 2023 | finance.yahoo.com

AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)

April 30, 2023 | finance.yahoo.com

When Will AnaptysBio, Inc. (NASDAQ:ANAB) Breakeven?

April 26, 2023 | finance.yahoo.com

Will AnaptysBio, Inc. (ANAB) Report Negative Q1 Earnings? What You Should Know

April 13, 2023 | msn.com

JP Morgan Maintains AnaptysBio (ANAB) Underweight Recommendation

See More Headlines

Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

ANAB Company Calendar

Last Earnings: 8/07/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ANAB
CUSIP: N/A
CIK: 1370053
Web: www.anaptysbio.com
Phone: (858) 362-6295
Fax: N/A
Employees: 96
Year Founded: 2005

Price Target and Rating

Average Stock Price Forecast: $34.75
High Stock Price Forecast: $45.00
Low Stock Price Forecast: $26.00
Forecasted Upside/Downside: +93.5%
Consensus Rating: Hold
Rating Score (0-4): 2.40
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.19)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-128,720,000.00
Net Margins: -1,113.38%
Pretax Margin: -1,113.19%
Return on Equity: -65.52%
Return on Assets: -25.07%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.53
Quick Ratio: 10.53

Sales & Book Value

Annual Sales: $10.29 million
Price / Sales: 46.34
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.22 per share
Price / Book: 1.95

Miscellaneous

Outstanding Shares: 26,550,000
Free Float: 17,122,000
Market Cap: $476.84 million
Optionable: Optionable
Beta: -0.16

Social Links

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Daniel R. Faga (Age 43)
Pres, CEO & Director
Comp: $867.12k

Mr. Eric J. Loumeau (Age 60)
Chief Legal Officer
Comp: $685.59k

Dr. James N. Topper M.D. (Age 61)
Ph.D., Advisor
Comp: $86.5k

Mr. Hamza Suria M.B.A. (Age 47)
M.Sc., Advisory
Comp: $3.06M

Dr. Paul F. Lizzul FAAD (Age 48)
M.B.A., M.D., M.P.H., Ph.D., Chief Medical Officer
Comp: $656.36k

Mr. Dennis M. Mulroy (Age 68)
Chief Financial Officer

Mr. Benjamin Stone
Sr. VP of Corp. Devel.

Ms. Beth Mueller
Sr. VP of HR

Dr. Martin Dahl Ph.D.
Sr. VP of Research

Mr. Douglas A. Rich M.B.A (Age 54)
M.B.A., Sr. VP of CMC

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ANAB Stock - Frequently Asked Questions

Should I buy or sell AnaptysBio stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ANAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares.
View ANAB analyst ratings or view top-rated stocks.
What is AnaptysBio's stock price forecast for 2023?: 5 analysts have issued 1 year price objectives for AnaptysBio's shares. Their ANAB share price forecasts range from $26.00 to $45.00. On average, they anticipate the company's share price to reach $34.75 in the next twelve months. This suggests a possible upside of 93.5% from the stock's current price.
View analysts price targets for ANAB or view top-rated stocks among Wall Street analysts.
How have ANAB shares performed in 2023?: AnaptysBio's stock was trading at $30.99 at the beginning of 2023. Since then, ANAB stock has decreased by 42.0% and is now trading at $17.96.
View the best growth stocks for 2023 here.
When is AnaptysBio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ANAB earnings forecast.
How were AnaptysBio's earnings last quarter?: AnaptysBio, Inc. (NASDAQ:ANAB) issued its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.15. The biotechnology company earned $3.46 million during the quarter, compared to analyst estimates of $5.50 million. AnaptysBio had a negative net margin of 1,113.38% and a negative trailing twelve-month return on equity of 65.52%.
What ETF holds AnaptysBio's stock ?: Virtus LifeSci Biotech Clinical Trials ETF holds 5,859 shares of ANAB stock, representing 1.01% of its portfolio.

What other stocks do shareholders of AnaptysBio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).
When did AnaptysBio IPO?: (ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
What is AnaptysBio's stock symbol?: AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."
How do I buy shares of AnaptysBio?: Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AnaptysBio's stock price today?: One share of ANAB stock can currently be purchased for approximately $17.96.
How much money does AnaptysBio make?: AnaptysBio (NASDAQ:ANAB) has a market capitalization of $476.84 million and generates $10.29 million in revenue each year. The biotechnology company earns $-128,720,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis.
How can I contact AnaptysBio?: AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.anaptysbio.com. The biotechnology company can be reached via phone at (858) 362-6295 or via email at investors@anaptysbio.com.

This page (NASDAQ:ANAB) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial